Fig. 4.

Loss of functional FGF15 does not impair RGC development or central projections. (A and B) Immunolabeling of CALR/SYNP (A) or RBPMS/GAD67 (B) in Fgf15^−/− mutant and littermate control retinas. (Scale Bars, 50 µm.) (C) Immunolabeling for VGluT2 in P14 WT (C) and Fgf15^−/− mutant (C′) LGN. The vLGN and dLGN are outlined with dashed lines. (Scale Bars, 100 µm.) (D and E) Quantification of the average fluorescent intensity of immunolabeled VGluT2⁺ retinal terminals in the dLGN (B) and vLGN (C) in WT and Fgf15^−/− mutants. Data are shown as means ± SEM; a.u., arbitrary units of average fluorescent intensity.